We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Octopus Group

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Next Gen Human Gut Microbiome Tests Enable Comprehensive Gastrointestinal Testing

By LabMedica International staff writers
Posted on 14 Mar 2023
Print article
Image: The MetaXplore human gut microbiome testing product range has been launched in Australia (Photo courtesy of Microba Life Sciences)
Image: The MetaXplore human gut microbiome testing product range has been launched in Australia (Photo courtesy of Microba Life Sciences)

A new range of next-generation human gut microbiome tests provides diagnostic gastrointestinal health testing along with metagenomic gut microbiome analysis.

Microba Life Sciences Limited (Brisbane, Australia) has launched its next-generation testing product range, MetaXplore to healthcare professionals in Australia under a new brand, Co-Biome. The new MetaXplore range provides diagnostic gastrointestinal health testing along with metagenomic-driven gut microbiome analysis to deliver comprehensive gastrointestinal testing solutions for healthcare professionals. The range consists of three products MetaXplore, MetaXplore GI, and MetaXplore GI Plus.

The tests are intended for the detection of diagnostic and investigative gastrointestinal health markers (fecal calprotectin, fecal occult blood, lactoferrin, pancreatic elastase, secretory IgA, Zonulin, Fecal pH), along with diagnostic pathogens and parasites (E.coli pathotypes, C.difficile pathotypes, Campylobacter spp., Yersinia enterocolitica, Vibrio spp., Aeromonas spp., Salmonella spp., Giardia lamblia, Entamoeba histolytica, Cryptosporidium spp., Dientamoeba fragilis, Cyclospora cayetanensis). The tests provide complete microbiome profiling (microbial diversity, richness, and profiling of over 28,000+ microbial species including bacteria, fungi, parasite, and archaea detection, along with parasite detection of Blastocystis subtypes 1-9 and other eukaryotes). The results are available in an easy-to-interpret report format that is designed to aid efficient patient consultation for healthcare professionals.

“The new MetaXplore test range delivers an important advancement in how microbiome test information can be applied in a healthcare setting,” said Dr. Luke Reid, Microba’s Chief Executive Officer. “We continue to make progress at the forefront of this field to advance the application of microbiome testing in a healthcare setting towards a future where it can be routine in health and disease management, much like a blood test is today.”

“These new tests integrate traditional gastrointestinal pathology tools with Microba’s next-generation microbiome testing technology and the latest global research to significantly advance the utility of microbiome testing in a healthcare setting. This test range is expected to significantly expand the total addressable market for Microba’s testing products,” added Assoc Prof. Lutz Krause, Microba’s Chief Scientific Officer.

Related Links:
Microba Life Sciences Limited 

Gold Supplier
Urinalysis Dipstick Control
Dipper Urinalysis Dipstick Control
New
Parvovirus B19 IgG Immunoassay
AESKULISA Parvovirus B19 IgG
New
Mycoplasma Pneumoniae Assay
SeroMP
New
Silver Supplier
Deepwell Plates
Accumax Deepwell Plates

Print article

Channels

Clinical Chem.

view channel
Image: Brief schematic diagram of the detection principle and method (Photo courtesy of CAS)

Rapid, Non-Invasive Method Diagnoses Type 2 Diabetes by Sniffing Urinary Acetone

Over 90% of diabetes cases are attributed to Type 2 diabetes (T2D), a prevalent metabolic condition that is expected to impact 380 million individuals globally by 2025. Despite being highly accurate, the... Read more

Molecular Diagnostics

view channel
Image: The new assay enables accurate prognosis and detection data for those prone to esophageal cancer (Photo courtesy of Previse)

First-of-Its-Kind Test Helps Determine Future Risk of Esophageal Cancer

Esophageal cancer is among the most lethal cancers in the world and has a 20% five-year survival rate post-diagnosis. Barrett's esophagus is the sole precursor known and is a significant risk factor for... Read more

Immunology

view channel
Image: A genetic test could guide the use of cancer chemotherapy (Photo courtesy of Pexels)

Genetic Test Predicts Whether Bowel Cancer Patients Can Benefit From Chemotherapy

Late-stage bowel cancer patients usually undergo a series of chemotherapies and targeted medicines for cancer treatment. However, the responses to the last-line chemotherapy treatment trifluridine/tipiracil... Read more

Pathology

view channel
Image: Artificial intelligence predicts genetics of cancerous brain tumors in under 90 seconds (Photo courtesy of Michigan Medicine)

AI-Based Diagnostic Screening System Predicts Genetics of Cancerous Brain Tumors in 90 Seconds

The diagnosis and treatment of gliomas increasingly rely on molecular classification, as surgical benefits and risks vary depending on a patient's genetic makeup. Complete removal of the tumor can extend... Read more

Technology

view channel
Image: Live view of non-fluorescent specimens using the glowscope frame (Photo courtesy of Winona State University)

Device Converts Smartphone into Fluorescence Microscope for Just USD 50

Fluorescence microscopes are utilized to examine specimens labeled with fluorescent stains or expressing fluorescent proteins, like those tagged with green fluorescent protein. However, since these microscopes... Read more

Industry

view channel
Image: Roche and Lilly will collaborate on the development of Roche Diagnostics’ Elecsys Amyloid Plasma Panel (Photo courtesy of Roche)

Roche and Eli Lilly Collaborate on Innovative Blood Test for Early Diagnosis of Alzheimer's

Presently, obstacles to timely and precise diagnosis of Alzheimer's disease exist globally, resulting in as many as 75% of individuals exhibiting symptoms but lacking a formal diagnosis.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.